Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Gains from Sales and Divestitures: 2015-2020

Historic Gains from Sales and Divestitures for ImmunityBio (IBRX) over the last 6 years, with Dec 2020 value amounting to $648,336.

  • ImmunityBio's Gains from Sales and Divestitures fell 39.88% to $336,084 in Q2 2021 from the same period last year, while for Jun 2021 it was $336,084, marking a year-over-year decrease of 39.88%. This contributed to the annual value of $648,336 for FY2020, which is 64.11% up from last year.
  • Per ImmunityBio's latest filing, its Gains from Sales and Divestitures stood at $648,336 for FY2020, which was up 64.11% from $395,051 recorded in FY2019.
  • In the past 5 years, ImmunityBio's Gains from Sales and Divestitures registered a high of $648,336 during FY2020, and its lowest value of $172,330 during FY2018.
  • In the last 3 years, ImmunityBio's Gains from Sales and Divestitures had a median value of $395,051 in 2019 and averaged $405,239.
  • Per our database at Business Quant, ImmunityBio's Gains from Sales and Divestitures slumped by 54.61% in 2017 and then surged by 129.24% in 2019.
  • Over the past 5 years, ImmunityBio's Gains from Sales and Divestitures (Yearly) stood at $537,982 in 2016, then crashed by 54.61% to $244,209 in 2017, then declined by 29.43% to $172,330 in 2018, then spiked by 129.24% to $395,051 in 2019, then surged by 64.11% to $648,336 in 2020.